Psychedelics FDA publishes first draft guidance document for psychedelics research It aims to highlight relevant considerations for researchers investigating the therapeutic value of psychedelics Rowan DunneJune 23, 2023
Health and Safety FDA to reject medical device applications without cyberattack protection plans As many as 40 per cent of end-of-life devices have no protection at all against cyberattacks Joseph MortonMarch 31, 2023
Medical and Pharmaceutical Natera and RenaCARE aim for early detection of kidney disease Natera (NASDAQ:NTRA) acquired full enrolment for the RenaCARE (Renasight Clinical Application, Review and Evaluation) study, which is a prospective, multi-center clinical trial to determine... Joseph MortonAugust 11, 2022
Business The Mugglehead technology roundup: glowing health edition Here are five companies looking to improve our collective health in different ways. Joseph MortonJune 17, 2022
Cannabis Inadequate testing for CBD contaminants raises industry concerns: Leafreport Many distributors are choosing not to test their products for microbes, pesticides and heavy metals Rowan DunneMay 26, 2022
CBD Another bipartisan bill seeks to regulate CBD in US The FDA has been promising a speedy process to create rules for cannabidiol since 2019 Nick LabaDecember 3, 2021
CBD US Senate bill would finally allow CBD in food and drinks A bipartisan group of US senators want to mandate the FDA to regulate CBD as a dietary supplement to improve the hemp industry and... Jared GnamMay 19, 2021
News MindMed stock surges on Nasdaq listing approval After its stock jumped 66%, MindMed now rivals Compass Pathways as the world's most valuable psychedelic company Jared GnamApril 23, 2021
Industry update Low-THC weed led to poor results in major PTSD study US researchers seek DEA to permit potent pot production after long-awaited FDA-backed study shows weak weed ineffective at treating PTSD Jared GnamMarch 30, 2021
Industry update Charlotte’s Web bounces back in Q4 American CBD market leader reports 2020 sales of US$95.2M and positive results for a third-party liver toxicity study Jared GnamMarch 25, 2021